• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Spinal Cord Disorders - Pipeline Review, H2 2012 Product Image

Spinal Cord Disorders - Pipeline Review, H2 2012

  • ID: 2245223
  • September 2012
  • 273 pages
  • Global Markets Direct

Spinal Cord Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Spinal Cord Disorders - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Spinal Cord Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Cord Disorders. Spinal Cord Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Spinal Cord Disorders.
- A review of the Spinal Cord Disorders products under development by companies READ MORE >

2
List of Tables 7
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Spinal Cord Disorders Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Spinal Cord Disorders 12
Spinal Cord Disorders Therapeutics under Development by Companies 14
Spinal Cord Disorders Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 23
Comparative Analysis 23
Mid Clinical Stage Products 24
Comparative Analysis 24
Early Clinical Stage Products 25
Comparative Analysis 25
Discovery and Pre-Clinical Stage Products 26
Comparative Analysis 26
Spinal Cord Disorders Therapeutics – Products under Development by Companies 27
Spinal Cord Disorders Therapeutics – Products under Investigation by Universities/Institutes 32
Companies Involved in Spinal Cord Disorders Therapeutics Development 34
F. Hoffmann-La Roche Ltd. 34
NsGene A/S 35
Scil Technology Gmbh 36
Athersys, Inc. 37
Isis Pharmaceuticals, Inc. 38
Quark Pharmaceuticals, Inc. 39
Oxford BioMedica plc 40
Sangamo BioSciences, Inc. 41
Novartis AG 42
Acorda Therapeutics, Inc. 43
Daewoong Pharmaceutical Co., Ltd. 44
Paratek Pharmaceuticals, Inc. 45
Oxygen Biotherapeutics, Inc. 46
Proneuron Biotechnologies, Inc. 47
Neuralstem, Inc. 48
Kaken Pharmaceutical Co.,Ltd. 49
Lpath, Inc. 50
Mesoblast Ltd 51
All India Institute of Medical Sciences 52
Yuhan Corporation 53
KOLON LIFE SCIENCE INC. 54
Repligen Corporation 55
SYGNIS Pharma AG 56
Bukwang Pharmaceutical Co., Ltd. 57
LTT Bio-Pharma Co., Ltd. 58
Sucampo Pharmaceuticals, Inc. 59
NeuroVive Pharmaceutical AB 60
Asubio Pharmaceuticals, Inc. 61
D-Pharm Ltd. 62
StemCells, Inc. 63
AnaMar Medical AB 64
Trophos SA 65
Q Therapeutics, Inc. 66
Remedy Pharmaceuticals, Inc. 67
TissueGene, Inc. 68
BioArctic Neuroscience AB 69
AIM Therapeutics Inc. 70
Omeros Corporation 71
Stemedica Cell Technologies, Inc. 72
SanBio, Inc. 73
Sirnaomics, Inc. 74
Lipopharma 75
Kringle Pharma, Inc. 76
Nexgenix Pharmaceuticals, LLC 77
Genethon 78
RhinoCyte, Inc. 79
RNL BIO Co., Ltd. 80
Cognosci, Inc. 81
Prosensa Therapeutics B.V. 82
Spinal Cord Disorders – Therapeutics Assessment 83
Assessment by Monotherapy Products 83
Assessment by Combination Products 84
Assessment by Route of Administration 85
Assessment by Molecule Type 88
Drug Profiles 91
fingolimod hydrochloride - Drug Profile 91
BA-210 - Drug Profile 93
MultiStem - Drug Profile 96
Lpathomab - Drug Profile 98
DWP-431 - Drug Profile 99
LT-0101 - Drug Profile 100
SPI-017 - Drug Profile 101
DP-b99 - Drug Profile 102
ecraprost - Drug Profile 105
SY-300 - Drug Profile 106
RG-3039 - Drug Profile 107
oxycyte - Drug Profile 109
ZFP TFs For Nerve Regeneration - Drug Profile 111
Neu-2000 - Drug Profile 112
Neuroprotection And Neural Regeneration Program - Drug Profile 113
beraprost sodium SR - Drug Profile 114
AIM-101 - Drug Profile 115
olesoxime - Drug Profile 116
SMN1-G - Drug Profile 118
Chondroitinase Program - Drug Profile 119
GGF-2 - Drug Profile 121
SB-623 - Drug Profile 123
tetracycline - Drug Profile 124
ChronSeal - Drug Profile 126
NsG-34 - Drug Profile 128
NXD-30001 - Drug Profile 129
NsG-25 - Drug Profile 130
NsG-32 - Drug Profile 131
PN-277 - Drug Profile 132
sodium oxybate - Drug Profile 133
sodium phenylbutyrate - Drug Profile 134
cannabis - Drug Profile 135
valproic acid - Drug Profile 136
Valproic acid + Levocarnitine - Drug Profile 137
ATI-355 - Drug Profile 139
HuCNS-SC - Drug Profile 140
somatotropin - Drug Profile 142
dichlorphenamide - Drug Profile 143
AX-201 - Drug Profile 144
Humanized Mik-(Beta)-1 - Drug Profile 145
SB618 - Drug Profile 146
Granulocyte Colony Stimulating Factor - Drug Profile 147
SCI Project - Drug Profile 148
Q-Cells - Drug Profile 149
Kenalog + Sensorcaine - Drug Profile 151
lithium carbonate - Drug Profile 152
lithium carbonate - Drug Profile 154
TNF blocker - Drug Profile 156
SPI-3608 - Drug Profile 157
KUR-115 - Drug Profile 158
ISIS-SMNRx - Drug Profile 159
PRO-105 - Drug Profile 160
COG-112 - Drug Profile 161
Depakote + Carnitor - Drug Profile 162
Methylprednisolone - Drug Profile 164
glyburide - Drug Profile 165
GM-603 - Drug Profile 167
LPA-181 - Drug Profile 168
NSI-566RSC - Drug Profile 169
NSI-566RSC - Drug Profile 171
Pentoxifylline + Tocopherol Acetate + Clodronic Acid - Drug Profile 173
AM-80H - Drug Profile 174
autologous stem cell - Drug Profile 175
NeoFuse - Drug Profile 176
Umbilical Cord Blood Mononuclear Cell Transplant - Drug Profile 178
Umbilical Cord Blood Mononuclear Cell + Methylprednisolone - Drug Profile 180
Umbilical Cord Blood Mononuclear Cell + Methylprednisolone + Lithium Carbonate - Drug Profile 182
AC-105 - Drug Profile 184
autologous adipose derived mesenchymal stem cells - Drug Profile 185
STP-805 - Drug Profile 186
L-NAME + Midodrine Hydrochloride - Drug Profile 187
Growth Hormone - Drug Profile 188
Umbilical Cord Mesenchymal Stem Cell Transplantation - Drug Profile 189
bone marrow derived mesenchymal stem cell - Drug Profile 190
GPR-161 Antagonist - Drug Profile 191
Drug For Spinal Muscular Atrophy - Drug Profile 192
SUN-13837 - Drug Profile 193
NVP-015 - Drug Profile 194
NVP-016 - Drug Profile 195
Drug For Spinal Muscular Atrophy - Drug Profile 197
SC-0806 - Drug Profile 198
Spinal Muscular Atrophy Programme - Drug Profile 199
YH-14618 - Drug Profile 200
Lithium Carbonate + Umbilical Cord Blood Mononuclear Cell Transplant - Drug Profile 201
RE-003 - Drug Profile 203
Cs - Drug Profile 204
Autologous Bone Marrow Stem Cells - Drug Profile 205
fasudil - Drug Profile 207
TG-D - Drug Profile 208
TG-N - Drug Profile 209
Drug for Spinal Muscular Atrophy - Drug Profile 210
Drug For Spinal Cord Injury - Drug Profile 211
Spinal Cord Injury Program - Drug Profile 212
ST-01 - Drug Profile 213
Brilliant Blue G - Drug Profile 214
RhinoCytes - Drug Profile 215
ND-602 - Drug Profile 217
AP-325 - Drug Profile 218
Dalfampridine - Drug Profile 219
Autologous Adipose Tissue Derived Mesenchymal Stem Cells - Drug Profile 220
Autologous Schwann Cells - Drug Profile 221
Autologous Schwann Cells - Drug Profile 223
Valproate + Levocarnitine - Drug Profile 225
Stemedyne-Neural Stem Cells - Drug Profile 226
Spinal Cord Disorders Therapeutics – Drug Profile Updates 227
Spinal Cord Disorders Therapeutics – Discontinued Products 251
Spinal Cord Disorders Therapeutics - Dormant Products 252
Spinal Cord Disorders – Product Development Milestones 256
Featured News & Press Releases 256
Appendix 265
Methodology 265
Coverage 265
Secondary Research 265
Primary Research 265
Expert Panel Validation 265
Contact Us 266
Disclaimer 266

List of Tables
Number of Products Under Development for Spinal Cord Disorders, H2 2012 19
Products under Development for Spinal Cord Disorders – Comparative Analysis, H2 2012 20
Number of Products under Development by Companies, H2 2012 22
Number of Products under Development by Companies, H2 2012 (Contd..1) 23
Number of Products under Development by Companies, H2 2012 (Contd..2) 24
Number of Products under Development by Companies, H2 2012 (Contd..3) 25
Number of Products under Development by Companies, H2 2012 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 29
Comparative Analysis by Late Stage Development, H2 2012 30
Comparative Analysis by Mid Clinical Stage Development, H2 2012 31
Comparative Analysis by Early Clinical Stage Development, H2 2012 32
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 33
Products under Development by Companies, H2 2012 34
Products under Development by Companies, H2 2012 (Contd..1) 35
Products under Development by Companies, H2 2012 (Contd..2) 36
Products under Development by Companies, H2 2012 (Contd..3) 37
Products under Development by Companies, H2 2012 (Contd..4) 38
Products under Investigation by Universities/Institutes, H2 2012 39
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 40
F. Hoffmann-La Roche Ltd., H2 2012 41
NsGene A/S, H2 2012 42
Scil Technology Gmbh, H2 2012 43
Athersys, Inc., H2 2012 44
Isis Pharmaceuticals, Inc., H2 2012 45
Quark Pharmaceuticals, Inc., H2 2012 46
Oxford BioMedica plc, H2 2012 47
Sangamo BioSciences, Inc., H2 2012 48
Novartis AG, H2 2012 49
Acorda Therapeutics, Inc., H2 2012 50
Daewoong Pharmaceutical Co., Ltd., H2 2012 51
Paratek Pharmaceuticals, Inc., H2 2012 52
Oxygen Biotherapeutics, Inc., H2 2012 53
Proneuron Biotechnologies, Inc., H2 2012 54
Neuralstem, Inc., H2 2012 55
Kaken Pharmaceutical Co.,Ltd., H2 2012 56
Lpath, Inc., H2 2012 57
Mesoblast Ltd, H2 2012 58
All India Institute of Medical Sciences, H2 2012 59
Yuhan Corporation, H2 2012 60
KOLON LIFE SCIENCE INC., H2 2012 61
Repligen Corporation, H2 2012 62
SYGNIS Pharma AG, H2 2012 63
Bukwang Pharmaceutical Co., Ltd., H2 2012 64
LTT Bio-Pharma Co., Ltd., H2 2012 65
Sucampo Pharmaceuticals, Inc., H2 2012 66
NeuroVive Pharmaceutical AB, H2 2012 67
Asubio Pharmaceuticals, Inc., H2 2012 68
D-Pharm Ltd., H2 2012 69
StemCells, Inc., H2 2012 70
AnaMar Medical AB, H2 2012 71
Trophos SA, H2 2012 72
Q Therapeutics, Inc., H2 2012 73
Remedy Pharmaceuticals, Inc., H2 2012 74
TissueGene, Inc., H2 2012 75
BioArctic Neuroscience AB, H2 2012 76
AIM Therapeutics Inc., H2 2012 77
Omeros Corporation, H2 2012 78
Stemedica Cell Technologies, Inc., H2 2012 79
SanBio, Inc., H2 2012 80
Sirnaomics, Inc., H2 2012 81
Lipopharma, H2 2012 82
Kringle Pharma, Inc., H2 2012 83
Nexgenix Pharmaceuticals, LLC, H2 2012 84
Genethon, H2 2012 85
RhinoCyte, Inc., H2 2012 86
RNL BIO Co., Ltd., H2 2012 87
Cognosci, Inc., H2 2012 88
Prosensa Therapeutics B.V., H2 2012 89
Assessment by Monotherapy Products, H2 2012 90
Assessment by Combination Products, H2 2012 91
Assessment by Stage and Route of Administration, H2 2012 94
Assessment by Stage and Molecule Type, H2 2012 97
Spinal Cord Disorders Therapeutics – Drug Profile Updates 234
Spinal Cord Disorders Therapeutics – Discontinued Products 258
Spinal Cord Disorders Therapeutics – Dormant Products 259
Spinal Cord Disorders Therapeutics – Dormant Products (Contd..1) 260
Spinal Cord Disorders Therapeutics – Dormant Products (Contd..2) 261
Spinal Cord Disorders Therapeutics – Dormant Products (Contd..3) 262

List of Figures
Number of Products under Development for Spinal Cord Disorders, H2 2012 19
Products under Development for Spinal Cord Disorders – Comparative Analysis, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 27
Late Stage Products, H2 2012 30
Mid Clinical Stage Products, H2 2012 31
Early Clinical Stage Products, H2 2012 32
Discovery and Pre-Clinical Stage Products, H2 2012 33
Assessment by Monotherapy Products, H2 2012 90
Assessment by Combination Products, H2 2012 91
Assessment by Route of Administration, H2 2012 92
Assessment by Stage and Route of Administration, H2 2012 93
Assessment by Molecule Type, H2 2012 95
Assessment by Stage and Molecule Type, H2 2012 96

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos